Patent: 10,435,454
✉ Email this page to a colleague
Summary for Patent: 10,435,454
Title: | Immunotherapy against melanoma and other cancers |
Abstract: | A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma. |
Inventor(s): | Sonntag; Annika (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Mahr; Andrea (Tuebingen, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munich Schwabing, DE) |
Assignee: | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) |
Application Number: | 16/165,121 |
Patent Claims: | see list of patent claims |
Details for Patent 10,435,454
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2036-04-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |